William Pao Selected Research

Gefitinib (Iressa)

11/2017	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
2/2015	Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
9/2014	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
4/2013	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
10/2011	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
7/2011	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
6/2011	Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
5/2011	Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
4/2011	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
3/2011	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William Pao Research Topics

Disease

108	Neoplasms (Cancer) 01/2018 - 07/2003
70	Lung Neoplasms (Lung Cancer) 01/2018 - 09/2004
46	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2017 - 02/2004
46	Adenocarcinoma of Lung 10/2016 - 01/2005
9	Disease Progression 01/2018 - 02/2006
9	Adenocarcinoma 11/2013 - 03/2004
7	Melanoma (Melanoma, Malignant) 01/2016 - 01/2012
6	Carcinogenesis 06/2012 - 09/2003
3	Exanthema (Rash) 01/2018 - 04/2011
3	Fatigue 01/2018 - 04/2011
3	Colorectal Neoplasms (Colorectal Cancer) 04/2015 - 09/2003
3	Colonic Neoplasms (Colon Cancer) 07/2012 - 09/2003
3	Sarcoma (Soft Tissue Sarcoma) 01/2012 - 07/2003
3	Neoplasm Metastasis (Metastasis) 12/2011 - 09/2010
3	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 05/2011 - 06/2006
2	Diarrhea 01/2018 - 11/2017
2	Brain Neoplasms (Brain Tumor) 01/2018 - 11/2005
2	Genetic Predisposition to Disease (Genetic Predisposition) 02/2016 - 08/2007
2	Glioblastoma (Glioblastoma Multiforme) 12/2014 - 06/2009
2	Thyroid Neoplasms (Thyroid Cancer) 12/2014 - 11/2010
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2013 - 06/2011
2	Leukemia 01/2012 - 11/2010
2	Glioma (Gliomas) 11/2011 - 11/2005
2	Breast Neoplasms (Breast Cancer) 11/2011 - 03/2011
1	Nausea 01/2018
1	Paronychia 11/2017
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015
1	Ear Neoplasms 05/2015
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2015
1	Cholangiocarcinoma 12/2014
1	Clinical Deterioration 06/2014
1	Adenosquamous Carcinoma 11/2013

Drug/Important Bio-Agent (IBA)

64	ErbB Receptors (EGF Receptor)IBA 01/2018 - 02/2004
48	Tyrosine Kinase InhibitorsIBA 01/2018 - 03/2005
45	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 09/2004
40	Gefitinib (Iressa)FDA Link 11/2017 - 02/2004
32	Phosphotransferases (Kinase)IBA 01/2016 - 09/2004
25	Pharmaceutical PreparationsIBA 11/2017 - 02/2004
17	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2014 - 02/2004
15	DNA (Deoxyribonucleic Acid)IBA 07/2015 - 08/2005
8	Biological ProductsIBA 02/2016 - 11/2006
7	Cetuximab (Erbitux)FDA Link 11/2017 - 10/2009
7	AfatinibIBA 11/2017 - 10/2012
7	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 06/2015 - 11/2008
7	Proteins (Proteins, Gene)FDA Link 07/2011 - 09/2003
6	Anaplastic Lymphoma KinaseIBA 09/2014 - 12/2010
6	Biomarkers (Surrogate Marker)IBA 11/2011 - 06/2008
4	osimertinibIBA 01/2017 - 09/2014
4	CrizotinibIBA 09/2014 - 12/2011
4	Tyrosine (L-Tyrosine)FDA Link 01/2012 - 12/2007
4	Threonine (L-Threonine)FDA Link 11/2008 - 03/2005
3	Peptides (Polypeptides)IBA 01/2017 - 05/2011
3	NucleotidesIBA 07/2015 - 09/2012
3	Imatinib Mesylate (Gleevec)FDA Link 01/2015 - 08/2005
3	Everolimus FDA Link 10/2010 - 08/2007
3	tyrosine receptor (receptor, tyrosine)IBA 10/2009 - 11/2008
3	Methionine (L-Methionine)FDA Link 12/2007 - 03/2005
2	AgarIBA 01/2017 - 01/2014
2	rociletinibIBA 10/2016 - 12/2013
2	Carrier Proteins (Binding Protein)IBA 01/2016 - 07/2014
2	Guanine NucleotidesIBA 01/2016 - 07/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 09/2015 - 06/2009
2	Mitogen-Activated Protein KinasesIBA 09/2015 - 11/2008
2	RNA (Ribonucleic Acid)IBA 07/2015 - 12/2013
2	TOR Serine-Threonine KinasesIBA 06/2014 - 10/2010
2	Lapatinib (GW572016)FDA Link 03/2011 - 08/2005
2	CarcinogensIBA 06/2010 - 09/2009
2	Cisplatin (Platino)FDA LinkGeneric 12/2009 - 01/2008
2	Oncogene Proteins (Oncogene Protein)IBA 10/2009 - 09/2003
2	GTP Phosphohydrolases (GTPases)IBA 11/2006 - 01/2005
2	Doxycycline (Periostat)FDA LinkGeneric 06/2006 - 07/2003
1	Alanine Transaminase (SGPT)IBA 01/2018
1	HLA-A Antigens (HLA-A)IBA 01/2017
1	Cancer VaccinesIBA 01/2017
1	CateninsIBA 01/2017
1	CytokinesIBA 03/2016
1	Janus KinasesIBA 03/2016
1	ALW-II-41-27IBA 01/2016
1	GTP-Binding Proteins (G-Protein)IBA 01/2016
1	cyclo(Arg-Pro) (CI 4)IBA 12/2015
1	AmphiregulinIBA 09/2015
1	LigandsIBA 09/2015
1	trametinibIBA 09/2015
1	AZD 6244IBA 06/2015
1	Adenosine Monophosphate (AMP)IBA 12/2014
1	Insulin-Like PeptidesIBA 09/2014
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 08/2014
1	Sirolimus (Rapamycin)FDA Link 06/2014
1	MTOR InhibitorsIBA 06/2014
1	Mechanistic Target of Rapamycin Complex 1IBA 05/2014
1	human PMS2 proteinIBA 01/2014
1	Coal (Coals)IBA 11/2013

Therapy/Procedure

53	Therapeutics 01/2018 - 03/2005
12	Drug Therapy (Chemotherapy) 12/2014 - 01/2005
3	Aftercare (After-Treatment) 10/2016 - 03/2008
2	Immunotherapy 01/2018 - 01/2017
2	Precision Medicine 01/2018 - 05/2011
2	Adjuvant Chemotherapy 04/2009 - 01/2008
1	Radiotherapy 12/2014
1	Oral Administration 12/2013